Pre-IPO Duality Biotherapeutics - Has the Potential to Surpass RemeGen
Founder Zhu Zhongyuan's role in biotech landscape helped Duality secure a high starting point, but slower R&D progress is a concern.Potential for...
691 Views
ECM Weekly (16th Sep 2024) - Midea, Bajaj Housing, 99 Speed, P N Gadgil, Hozon, Trial, NextDC, Via
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
617 Views
Duality Biotherapeutics (映恩生物) Pre-IPO: Too Early, Too Ambitious
Duality biotherapeutics is looking to raise USD 300m in a Hong Kong listing. We look at its core products and key products, as well as its investor...
760 Views